Understanding Cardiovascular Events With JAK Inhibitors: Endothelial Effects

JAK inhibitors can suppress inflammatory signaling, yet their cardiovascular effects may not be uniform across drugs or biological endpoints. In a comparative human endothelial-cell study, Zavoriti and Miossec examined how six inhibitors affected cytokine release, adhesion molecules, coagulation-related gene expression, and apoptosis during combined TNF and IL-17A stimulation. The central finding is a useful caution for immune regulation research: lower inflammatory cytokine output did not consistently coincide with a less proadhesive or less procoagulant endothelial profile. The findings are reported in the reference study.

Study Background and Research Question

Rheumatoid arthritis is associated with greater cardiovascular disease incidence than in the general population, with chronic systemic inflammation considered one contributor. TNF and IL-17A are relevant to this context because they can cooperate to activate endothelial cells. In experimental systems, this combination promotes cytokine and chemokine production, increases surface adhesion molecules that support leukocyte recruitment, and shifts coagulation-related regulation toward a more prothrombotic state. Endothelial injury and apoptosis may further impair vascular function.

JAK inhibitors are used in several inflammatory and hematologic settings, but TNF and IL-17A do not directly signal through the JAK-STAT signaling pathway. This distinction frames the study’s question: when endothelial cells are exposed to TNF plus IL-17A, do different JAK inhibitors nonetheless alter inflammatory and vascular-associated outcomes, and are those effects consistent across drugs? The study was not a clinical comparison of cardiovascular events. It used a cellular model to investigate possible differences in endothelial responses.

Key Innovation from the Reference Study

The study’s main contribution is its multi-endpoint comparison. Rather than treating suppression of a single inflammatory cytokine as a proxy for vascular benefit, the authors examined cytokine release alongside adhesion-related genes, coagulation and fibrinolysis factors, and cell apoptosis. They compared tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib in the same inflammatory endothelial-cell setting, helping reveal both compound-specific effects and concentration-sensitive responses.

This design matters because endothelial dysfunction is not captured by IL-6 alone. Adhesion molecules may influence leukocyte-endothelial interactions, tissue factor is linked to procoagulant activity, and thrombomodulin contributes to anticoagulant regulation. A treatment that changes one component may leave others unchanged or shift them in an unfavorable direction. The paper therefore offers a more differentiated view of vascular effects than an assay focused only on general inflammatory output.

Methods and Experimental Design Insights

The investigators induced a strong inflammatory response in human vascular endothelial cells using TNF together with IL-17A. Cells were treated or left untreated with each of the six JAK inhibitors at 1 or 10 μM. IL-6 and IL-8 in the culture medium were measured by enzyme-linked immunosorbent assay. Quantitative reverse-transcription polymerase chain reaction was used to assess expression changes in adhesion molecules and factors associated with coagulation and fibrinolysis. Annexin V staining was used to assess endothelial apoptosis. These design details and the reported outcomes are summarized in the published study.

Comparing multiple endpoints under a common stimulus helps distinguish general anti-inflammatory activity from changes in endothelial phenotype. However, the 1 and 10 μM exposures are experimental conditions, not clinical dose recommendations. In particular, the study does not by itself establish that the concentrations correspond to free drug exposures in patients. When interpreting or replicating the work, readers should consult the full methods for cytokine doses, treatment timing, cell-culture conditions, and assay normalization details rather than inferring those parameters from the abstract-level findings.

Protocol Parameters

• Inflammatory challenge: The study stimulated human vascular endothelial cells with TNF plus IL-17A; consult the full article for the exact cytokine concentrations and exposure schedule before replication. The reference study reports the model and outcome measures.
• Inhibitor concentrations: The published comparison tested each inhibitor at 1 and 10 μM. Treat these as study conditions, analyze the concentrations separately, and do not assume they predict clinical exposure or effects at other concentrations.
• Readout panel: The paper measured secreted IL-6 and IL-8 by ELISA, gene-expression changes in adhesion and coagulation/fibrinolysis-related factors by quantitative reverse-transcription PCR, and apoptosis by Annexin V staining. A replication workflow should retain distinct readouts rather than using cytokine suppression as the sole efficacy measure.
• Interpretation controls: As a workflow recommendation, include unstimulated, cytokine-stimulated, and vehicle-matched conditions, and assess viability alongside molecular endpoints. These controls help separate changes in gene expression from effects associated with cytotoxicity; they are recommendations for experimental interpretation, not a claim that every control was specified in the abstract.

Core Findings and Why They Matter

All six inhibitors reduced IL-6 release from endothelial cells stimulated with TNF plus IL-17A. The reduction in IL-8 was more selective: only baricitinib and fedratinib decreased the overproduction at 1 μM. Thus, even the cytokine readouts did not respond identically across the drug panel. Lower IL-6, in particular, should not be read as evidence that every other inflammatory or vascular-associated feature has normalized.

Adhesion-molecule responses also varied. Fedratinib reduced the cytokine-induced increase in VCAM-1 and E-selectin at both tested concentrations. Tofacitinib reduced induction of ICAM-1 and E-selectin at 1 μM. In contrast, at 10 μM, tofacitinib, baricitinib, upadacitinib, peficitinib, and ruxolitinib enhanced TNF-plus-IL-17A-induced VCAM-1 and ICAM-1 expression. This concentration-dependent result emphasizes that inhibitor effects on endothelial markers cannot be generalized from drug class alone.

The coagulation-associated outcomes added another layer. Peficitinib and fedratinib reduced the induced expression of tissue factor at both concentrations tested, while ruxolitinib did so only at 1 μM. None of the inhibitors prevented the cytokine-associated down-regulation of thrombomodulin. Fedratinib and peficitinib were also proapoptotic and cytotoxic to endothelial cells under the study conditions. These findings illustrate why molecular changes should be considered together with cell survival: a decrease in one procoagulant marker does not necessarily imply a broadly protective endothelial response.

Overall, all six agents showed an anti-inflammatory effect on IL-6 release in this model, but most did not consistently prevent adhesion-molecule induction or the broader shift in coagulation-related markers. The authors’ results support a measured conclusion: endothelial responses differed by compound, endpoint, and concentration. They do not demonstrate that any one of these cell-culture profiles causes or prevents cardiovascular events in patients.

Comparison with Existing Internal Articles

The internal overview JAK Inhibitors and Endothelial Cardiovascular Effects also emphasizes that cytokine reduction does not guarantee correction of adhesion, coagulation, or cell-survival abnormalities. The reference study provides a more granular account of that point by reporting which markers changed with each inhibitor and by highlighting concentration-dependent differences. The overview is useful as a broad orientation, whereas the primary study should guide interpretation of the specific experimental findings.

A separate internal article, Tofacitinib Citrate (CP-690550 citrate): Selective JAK3 inhibitor, discusses tofacitinib in the context of immune and JAK-STAT research. That mechanistic framing is relevant to immune-cell experiments, but it should not be used to infer that the endothelial findings here are caused by JAK3 selectivity. The comparison study did not establish a JAK-subtype mechanism for the observed vascular responses, and TNF and IL-17A themselves do not directly signal through JAK-STAT.

Limitations and Transferability

This was an in vitro study of human endothelial cells, not a trial or observational analysis of cardiovascular outcomes. A combined TNF-plus-IL-17A challenge models a defined inflammatory context but cannot reproduce the full range of chronic disease conditions, circulating cells, vascular flow, drug metabolism, or tissue exposure in a patient. The measured endpoints are biologically relevant indicators, but they are not equivalent to thrombosis, myocardial infarction, stroke, or other clinical events.

Concentration is another interpretive boundary. The two tested levels allow a comparison within the experimental model, but they should not be treated as a clinical dose-response curve. Nor does the study establish whether differences would persist across endothelial sources, longer exposure periods, or other inflammatory environments. Finally, because the initiating cytokines do not directly activate JAK-STAT, the results do not show that the inhibitors directly block TNF or IL-17A signaling. Any contribution from secondary signaling or network interactions would require further experimental testing.

For inflammatory disorder research, the practical implication is methodological: assess several vascular-relevant endpoints and cell viability, and distinguish an anti-inflammatory readout from evidence of endothelial protection. The paper motivates further investigation of inhibitor-specific effects, but its data should not be used alone to rank clinical cardiovascular safety.

Research Support Resources

For separate JAK-STAT and immune-cell workflows, researchers can use Tofacitinib citrate (CP-690550 citrate) (SKU A4135) as a research reagent. The endothelial study discussed here tested its own experimental conditions and does not establish a recommended concentration or clinical interpretation for this product.